Entera Bio Receives Positive FDA Feedback on Osteoporosis Pill Trial

Key Facts

In a move reflecting vital progress within the biotechnology sector, Entera Bio has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its Phase 3 protocol for EB613. This regulatory feedback specifically concerns the study design for the company's oral anabolic treatment for osteoporosis. According to reports, this positive response establishes a clear regulatory path toward potential approval for what could be a first-of-its-kind oral therapy.

This development comes as the healthcare sector seeks non-invasive alternatives to current anabolic treatments that are only available via injection, such as Eli Lilly’s Forteo. Compared to peers, Entera Bio’s success in advancing EB613 to Phase 3 strengthens its position in a global osteoporosis market projected to reach $16 billion by 2030 (per Grand View Research data).

Regarding market performance, ENTX stock stood at $1.21 (at close June 18, 2026) after reaching a daily high of $1.22. Investors are now watching for the official commencement of Phase 3 trials as a primary catalyst, while also monitoring broader macro indicators like U.S. Retail Sales and global interest rate decisions which may impact risk appetite for micro-cap biotech firms.